Navigation Links
Feldenkrais(R) Movement Institute Announces Simple Non-Surgical Solutions for Jaw and Facial Pain (TMJ)
Date:5/18/2009

Do-It-Yourself exercises help reduce stress-related TMJ problems and create healthy, pain-free habits

BERKELEY, Calif., May 18 /PRNewswire/ -- The Feldenkrais Movement Institute announces the release of The Intelligent Body(R) TMJ Program as part of its The Intelligent Body(R) DIY-series of movement reeducation lessons available on CD. The program offers sufferers of jaw pain an inexpensive and effective self-care method to help reduce chronic tension in the jaw, face, neck and upper back. The lessons also reverse long-standing movement habits often responsible for the original TMJ symptoms.

TMJ-related problems such as headaches and grinding teeth (bruxism) have been on the rise as the current economic downturn causes increased stress in people. These problems, while often triggered by outside factors, are increasingly recognized as being related to improper postural habits. Frank Wildman, Ph.D., Director of The Feldenkrais Movement Institute, designed the Intelligent Body(R) TMJ Program to help reverse many people's longstanding habits that create tension and stress and replace them with healthy patterns of movement. This Program contains six lessons, each averaging 10 minutes in length. The lessons are based on the Feldenkrais Method(R) and teach sufferers of jaw and facial pain new ways of using their muscles. When practiced with regularity, these easy, DIY-exercises can relieve pain and improve posture.

Dr. Wildman explains: "Most people don't realize how postural habits can significantly affect their jaws, or how a problematic jaw can be at the root of headaches, bruxism, neck and facial pain, and other health challenges. I wanted to create a Feldenkrais program to specifically address postural and
'/>"/>

SOURCE The Feldenkrais Movement Institute
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
2. New Research Reveals Unforeseen Side Effect of the Breast Cancer Movement
3. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
4. Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidones Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events
5. Lions Eye Institute for Transplant & Research, Inc. Launches Multi-Million Dollar, State-of-the-Art Research Institute that Will Advance the Study of Blinding Eye Diseases
6. Karmanos Cancer Institute Researchers Study New Drug Combinations to Treat Childhood Leukemia
7. Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference
8. Midwest Research Institute Launches Clinical Molecular Diagnostics Laboratory
9. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
10. Research Teams at J. Craig Venter Institute and Ludwig Institute for Cancer Research Uncover New Chromosomal Alterations in Cancer Using Transcriptome Sequencing Approach
11. Roskamp Institute Identifies New Class of Drugs to Treat Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3Hospital Financials Have Recovered to Pre Recession Levels According to Thomson Reuters Study 60953 1Hospital Financials Have Recovered to Pre Recession Levels According to Thomson Reuters Study 60953 2Hospital Financials Have Recovered to Pre Recession Levels According to Thomson Reuters Study 60953 3Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin 60950 1Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin 60950 2Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 6076 1Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 6076 2Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 6076 3
Other Medicine Technology:CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 2CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 3CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 4CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 5CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 6CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 7CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 8CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 9CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 10Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 2Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 3Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 4Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 5Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 6Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 7
Breaking Medicine News(10 mins):Health News:Union Hospital, Hong Kong, Selects First DataBank's Electronic Drug Information in Medication Safety Initiative 2Health News:Union Hospital, Hong Kong, Selects First DataBank's Electronic Drug Information in Medication Safety Initiative 3Health News:Wellness Manufacturer Wins Two 2009 American Spa Awards 2Health News:Obesity and Inactivity -- The Biggest Threat to the Nation's Health 2Health News:Obesity and Inactivity -- The Biggest Threat to the Nation's Health 3Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 2Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 3Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 4Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 5Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 6Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 7Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 8Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 9Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 10Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 11Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 2Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 3Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 4Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 5